Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2013

Open Access 01-12-2013 | Review

The role of peptide and DNA vaccines in myeloid leukemia immunotherapy

Authors: Chen Lin, Yangqiu Li

Published in: Cancer Cell International | Issue 1/2013

Login to get access

Abstract

While chemotherapy and targeted therapy are successful in inducing the remission of myeloid leukemia as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), the disease remains largely incurable. This observation is likely due to the drug resistance of leukemic cells, which are responsible for disease relapse. Myeloid leukemia vaccines may most likely be beneficial for eradicating minimal residual disease after treatment with chemotherapy or targeted therapy. Several targeted immunotherapies using leukemia vaccines have been heavily investigated in clinical and preclinical trials. This review will focus on peptides and DNA vaccines in the context of myeloid leukemias, and optimal strategies for enhancing the efficacy of vaccines based on myeloid leukemia immunization are also summarized.
Literature
1.
Yong AS, Keyvanfar K, Eniafe R, Savani BN, Rezvani K, Sloand EM, Goldman JM, Barrett AJ: Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia. 2008, 22 (9): 1721-1727. 10.1038/leu.2008.161.PubMedCentralCrossRefPubMed
2.
Ali N, Adil SN, Shaikh MU, Moosajee M, Masood N: Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011. Exp Hematol Oncol. 2012, 1 (1): 13-10.1186/2162-3619-1-13.PubMedCentralCrossRefPubMed
3.
4.
Collins RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997, 15 (2): 433-434.PubMed
5.
Goldman JM, Druker BJ: Chronic myeloid leukemia: current treatment options. Blood. 2001, 98 (7): 2039-2042. 10.1182/blood.V98.7.2039.CrossRefPubMed
6.
Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979, 300 (19): 1068-1073. 10.1056/NEJM197905103001902.CrossRefPubMed
7.
Greiner J, Dohner H, Schmitt M: Cancer vaccines for patients with acute myeloid leukemia – definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica. 2006, 91 (12): 1653-1661.PubMed
8.
Harty JT, Badovinac VP: Shaping and reshaping CD8 + T-cell memory. Nat Rev Immunol. 2008, 8 (2): 107-119. 10.1038/nri2251.CrossRefPubMed
9.
Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, Heslop HE, Rooney CM, Pane F, Savoldo B: Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood. 2008, 112 (5): 1876-1885. 10.1182/blood-2008-04-150045.PubMedCentralCrossRefPubMed
10.
Rezvani K, Yong AS, Mielke S, Jafarpour B, Savani BN, Le RQ, Eniafe R, Musse L, Boss C, Kurlander R, Barrett AJ: Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica. 2011, 96 (3): 432-440. 10.3324/haematol.2010.031674.PubMedCentralCrossRefPubMed
11.
Li Y, Lin C, Schmidt CA: New insights into antigen specific immunotherapy for chronic myeloid leukemia. Cancer Cell Int. 2012, 12: 52-10.1186/1475-2867-12-52.PubMedCentralCrossRefPubMed
12.
Stevenson FK, Ottensmeier CH, Rice J: DNA vaccines against cancer come of age. Curr Opin Immunol. 2010, 22 (2): 264-270. 10.1016/j.coi.2010.01.019.CrossRefPubMed
13.
Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I, Stevenson F, Ottensmeier CH: DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther. 2009, 20 (11): 1269-1278. 10.1089/hum.2009.067.CrossRefPubMed
14.
Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, McCann KJ, Roddick JS, King AT, McNicholl F, Savelyeva N, Rice J: DNA vaccines to attack cancer. Proc Natl Acad Sci U S A. 2004, 101 (Suppl 2): 14646-14652.PubMedCentralCrossRefPubMed
15.
Rinaldi M, Ria F, Parrella P, Signori E, Serra A, Ciafrè SA, Vespignani I, Lazzari M, Farace MG, Saglio G, Fazio VM: Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients’ tumor cells. Cancer Res. 2001, 161 (4): 1555-1562.
16.
Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002, 99 (5): 1517-1526. 10.1182/blood.V99.5.1517.CrossRefPubMed
17.
Maecker HT, Umetsu DT, DeKruyff RH, Levy S: Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC. Immunology. 1998, 161 (12): 6532-6536.
18.
Chan K, Lee DJ, Schubert A, Tang CM, Crain B, Schoenberger SP, Corr M: The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA. J Immunol. 2001, 166 (5): 3061-3066.CrossRefPubMed
19.
Pfaar O, Cazan D, Klimek L, Larenas-Linnemann D, Calderon MA: Adjuvants for immunotherapy. Curr Opin Allergy Clin Immunol. 2012, 12 (6): 648-657. 10.1097/ACI.0b013e32835a11d6.CrossRefPubMed
20.
Wang Z, Choi MK, Ban T, Yanai H, Negishi H, Lu Y, Tamura T, Takaoka A, Nishikura K, Taniguchi T: Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc Natl Acad Sci USA. 2008, 105 (14): 5477-5482. 10.1073/pnas.0801295105.PubMedCentralCrossRefPubMed
21.
Burckstummer T, Baumann C, Bluml S, Dixit E, Durnberger G, Jahn H, Planyavsky M, Bilban M, Colinge J, Bennett KL, Superti-Furga G: An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol. 2009, 10 (3): 266-272. 10.1038/ni.1702.CrossRefPubMed
22.
Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT: Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol. 2000, 38 (2): 208-217. 10.1159/000020281.CrossRefPubMed
23.
Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE: Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther. 2003, 14 (8): 709-714. 10.1089/104303403765255110.PubMedCentralCrossRefPubMed
24.
Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS: Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer. 2003, 98 (1): 144-154. 10.1002/cncr.11462.CrossRefPubMed
25.
Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R: Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 2002, 62 (20): 5845-5852.PubMed
26.
Zha X, Yan X, Shen Q, Zhang Y, Wu X, Chen S, Li B, Yang L, Geng S, Weng J, Du X, Li Y: Alternative expression of TCRζ related genes in patients with chronic myeloid leukemia. J Hematol Oncol. 2012, 5: 74-10.1186/1756-8722-5-74.PubMedCentralCrossRefPubMed
27.
Rojas JM, Knight K, Watmough S, Bell J, Wang L, Callaghan T, Clark RE: BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients. Leuk Res. 2011, 35 (3): 369-372. 10.1016/j.leukres.2010.05.028.CrossRefPubMed
28.
Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA: A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004, 103 (3): 1037-1042.CrossRefPubMed
29.
Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, Amabile M, Forconi F, Gozzetti A, Raspadori D, Amadori S, Lauria F: Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005, 365 (9460): 657-662.CrossRefPubMed
30.
Kessler JH, Bres-Vloemans SA, van Veelen PA, de Ru A, Huijbers IJ, Camps M, Mulder A, Offringa R, Drijfhout JW, Leeksma OC, Ossendorp F, Melief CJ: BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes. Leukemia. 2006, 20 (10): 1738-1750. 10.1038/sj.leu.2404354.CrossRefPubMed
31.
Maslak PG, Dao T, Gomez M, Chanel S, Packin J, Korontsvit T, Zakhaleva V, Pinilla-Ibarz J, Berman E, Scheinberg DA: A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukemia. 2008, 22 (8): 1613-1616. 10.1038/leu.2008.7.CrossRefPubMed
32.
Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, Cohen EN, Ebarb T, Scheinberg DA, Cortes J: Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer. 2009, 115 (17): 3924-3934. 10.1002/cncr.24468.CrossRefPubMed
33.
Breccia M, Bocchia M, Cannella L, Defina M, Ippoliti M, Loglisci G, Santopietro M, Lauria F, Alimena G: Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance. Br J Haematol. 2010, 150 (2): 240-242.PubMed
34.
Lucansky V, Sobotkova E, Tachezy R, Duskova M, Vonka V: DNA vaccination against bcr-abl-positive cells in mice. Int J Oncol. 2009, 35 (4): 941-951.PubMed
35.
Osman Y, Takahashi M, Zheng Z, Toba K, Liu A, Furukawa T, Narita M, Aizawa Y, Koike T, Shibata A: Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy. J Exp Clin Cancer Res. 1999, 18 (4): 485-492.PubMed
36.
Padua RA, Chomienne C: Use of animal models for the treatment of leukemias: Efficacy of DNA vaccination combined with ATRA. Discov Med. 2004, 4 (20): 41-44.PubMed
37.
Padua RA, Larghero J, Robin M, le Pogam C, Schlageter MH, Muszlak S, Fric J, West R, Rousselot P, Phan TH, Mudde L, Teisserenc H, Carpentier AF, Kogan S, Degos L, Pla M, Bishop JM, Stevenson F, Charron D, Chomienne C: PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med. 2003, 9 (11): 1413-1417. 10.1038/nm949.CrossRefPubMed
38.
Pollock JL, Lane AA, Schrimpf K, Ley TJ: Murine acute promyelocytic leukemia cells can be recognized and cleared in vivo by adaptive immune mechanisms. Haematologica. 2005, 90 (8): 1042-1049.PubMed
39.
Furugaki K, Pokorna K, Le Pogam C, Aoki M, Reboul M, Bajzik V, Krief P, Janin A, Noguera ME, West R, Charron D, Chomienne C, Pla M, Moins-Teisserenc H, Padua RA: DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model. Blood. 2010, 115 (3): 653-656. 10.1182/blood-2007-08-109009.CrossRefPubMed
40.
Oka Y, Tsuboi A, Kawakami M, Elisseeva OA, Nakajima H, Udaka K, Kawase I, Oji Y, Sugiyama H: Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr Med Chem. 2006, 13 (20): 2345-2352. 10.2174/092986706777935104.CrossRefPubMed
41.
Ochsenreither S, Fusi A, Busse A, Bauer S, Scheibenbogen C, Stather D, Thiel E, Keilholz U, Letsch A: “Wilms Tumor Protein 1” (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow. J Immunother. 2011, 34 (1): 85-91. 10.1097/CJI.0b013e3181f3cc5c.CrossRefPubMed
42.
Ochsenreither S, Fusi A, Geikowski A, Stather D, Busse A, Stroux A, Letsch A, Keilholz U: Wilms’ tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer Immunol Immunother. 2012, 61 (3): 313-322. 10.1007/s00262-011-1099-y.CrossRefPubMed
43.
Oji Y, Oka Y, Nishida S, Tsuboi A, Kawakami M, Shirakata T, Takahashi K, Murao A, Nakajima H, Narita M, Takahashi M, Morita S, Sakamoto J, Tanaka T, Kawase I, Hosen N, Sugiyama H: WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient. Eur J Haematol. 2010, 85 (4): 358-360. 10.1111/j.1600-0609.2010.01497.x.CrossRefPubMed
44.
Saitoh A, Narita M, Watanabe N, Tochiki N, Yamahira A, Nakamura T, Kaji M, Masuko M, Furukawa T, Toba K, Fuse I, Aizawa Y, Takahashi M: WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval. Med Oncol. 2011, 28 (1): 219-230. 10.1007/s12032-010-9425-3.CrossRefPubMed
45.
Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Li H, Kawasaki K, Aozasa K, Kishimoto T, Udaka K, Sugiyama H: Cytotoxic T-lymphocyte responses elicited to Wilms’ tumor gene WT1 product by DNA vaccination. J Clin Immunol. 2000, 20 (3): 195-202. 10.1023/A:1006637529995.CrossRefPubMed
46.
Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M, Vittes GE, Molinier-Frenkel V, Farcet JP, Stauss HJ, Delfau-Larue MH, Stevenson FK: DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood. 2008, 112 (7): 2956-2964. 10.1182/blood-2008-02-137695.CrossRefPubMed
47.
Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, Döhner H, Schmitt M: mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer. 2004, 108 (5): 704-711. 10.1002/ijc.11623.CrossRefPubMed
48.
Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S, Mims M, Luciano L, Shafer J, Leen AM, Heslop HE, Rooney CM, Pane F, Brenner MK, Savoldo B: High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood. 2011, 117 (12): 3353-3362. 10.1182/blood-2010-08-300376.PubMedCentralCrossRefPubMed
49.
Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N, Fukushima P, Barrett AJ: Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996, 88 (7): 2450-2457.PubMed
50.
Qazilbash MH, Wieder E, Rios R, Lu S, Kant S, Giralt S, Estey EH, Thall P, de Lima M, Couriel D, Champlin RE, Komanduri K, Molldrem JJ: Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia [abstract]. Blood. 2004, 104: 259-(ASH Annual Meeting Abstracts)
51.
Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, Jafarpour B, Boss C, Barrett AJ: Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008, 111 (1): 236-242. 10.1182/blood-2007-08-108241.PubMedCentralCrossRefPubMed
52.
Greiner J, Schmitt A, Giannopoulos K, Rojewski MT, Götz M, Funk I, Ringhoffer M, Bunjes D, Hofmann S, Ritter G, Döhner H, Schmitt M: High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica. 2010, 95 (7): 1191-1197. 10.3324/haematol.2009.014704.PubMedCentralCrossRefPubMed
53.
Tzankov A, Strasser U, Dirnhofer S, Menter T, Arber C, Jotterand M, Rovo A, Tichelli A, Stauder R, Günthert U: In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival. Ann Hematol. 2011, 90 (8): 901-909. 10.1007/s00277-011-1159-6.CrossRefPubMed
54.
Li Z, Qiao Y, Liu B, Laska EJ, Chakravarthi P, Kulko JM, Bona RD, Fang M, Hegde U, Moyo V, Tannenbaum SH, Ménoret A, Gaffney J, Glynn L, Runowicz CD, Srivastava PK: Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res. 2005, 11 (12): 4460-4468. 10.1158/1078-0432.CCR-05-0250.CrossRefPubMed
55.
Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D: A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol. 2011, 4: 46-10.1186/1756-8722-4-46.PubMedCentralCrossRefPubMed
56.
Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C: A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009, 113 (26): 6541-6548. 10.1182/blood-2009-02-202598.CrossRefPubMed
57.
Cen D, Hu G, Zhou Y, Yang L, Chen S, Schmidt CA, Li Y: Enhancement of specific cellular immune response induced by DNA vaccines encoding PML-RARalpha and hIL-2 genes. Hematology. 2010, 15 (2): 88-95. 10.1179/102453310X125833470096589073.CrossRefPubMed
58.
Ji MC, Jiang YW, Liu W, Guan J, Qian L, Gong WJ: Immune protective mechanisms of gene vaccines with co-expressing bcr-abl fusion gene fragment and mouse IL-7 gene. Zhonghua Zhong Liu Za Zhi. 2007, 29 (2): 93-95. ChinesePubMed
59.
Tao K, Li YJ, Wang D, Qi JY, Deng YP, Wang HX, Hu J, Feng WL: Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mIL-12. Cancer Biol Ther. 2011, 12 (10): 881-887. 10.4161/cbt.12.10.17674.PubMedCentralCrossRefPubMed
60.
Šmahel M, Poláková I, Sobotková E, Vajdová E: Systemic administration of CpG oligodeoxynucleotide and levamisole as adjuvants for gene-gun-delivered antitumor DNA vaccines. Clin Dev Immunol. 2011, 2011: 176759-PubMedCentralPubMed
61.
Eslami NS, Shokrgozar MA, Mousavi A, Azadmanesh K, Nomani A, Apostolopoulos V, Day S, Amanzadeh A, Alimohammadian MH: Simultaneous immunisation with a Wilms’ tumour 1 epitope and its ubiquitin fusions results in enhanced cell mediated immunity and tumour rejection in C57BL/6 mice. Mol Immunol. 2012, 51 (3–4): 325-331.CrossRefPubMed
62.
Shen C, Hao SG, Zhao CX, Zhu J, Wang C: Antileukaemia immunity: effect of exosomes against NB4 acute promyelocytic leukaemia cells. J Int Med Res. 2011, 39 (3): 740-747.CrossRefPubMed
63.
Liu MA: DNA vaccines: an historical perspective and view to the future. Immunol Rev. 2011, 239 (1): 62-84. 10.1111/j.1600-065X.2010.00980.x.CrossRefPubMed
64.
Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, Lollini PL, Musiani P, Forni G, Cavallo F: Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res. 2004, 64 (8): 2858-2864. 10.1158/0008-5472.CAN-03-2962.CrossRefPubMed
65.
Curcio C, Khan AS, Amici A, Spadaro M, Quaglino E, Cavallo F, Forni G, Draghia-Akli R: DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Ther. 2008, 15 (2): 108-114. 10.1038/sj.cgt.7701106.CrossRefPubMed
66.
Cheung YK, Cheng SC, Sin FW, Xie Y: Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. Vaccine. 2004, 23 (5): 629-638. 10.1016/j.vaccine.2004.07.010.CrossRefPubMed
Metadata
Title
The role of peptide and DNA vaccines in myeloid leukemia immunotherapy
Authors
Chen Lin
Yangqiu Li
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2013
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-13-13

Other articles of this Issue 1/2013

Cancer Cell International 1/2013 Go to the issue

Primary research

X-ray irradiation promotes apoptosis of hippocampal neurons through up-regulation of Cdk5 and p25

Primary research

Expression of MACC1 and c-Met in human gastric cancer and its clinical significance

Hypothesis

Cancer: a “stem-cell” disease?

Primary research

Si-RNA mediated knockdown of CELF1 gene suppressed the proliferation of human lung cancer cells

Primary research

Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway

Primary research

Low-dose etoposide-treatment induces endoreplication and cell death accompanied by cytoskeletal alterations in A549 cells: Does the response involve senescence? The possible role of vimentin
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits